# Evaluate The Utility Of 124I-cG250 for The Early Detection Of Response to Therapy In Patients With Metastatic Renal Cell Carcinoma

> **NCT01582204** · NA · ACTIVE_NOT_RECRUITING · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 17 (actual)

## Conditions studied

- Renal Cancer

## Interventions

- **DRUG:** 124IcG250

## Key facts

- **NCT ID:** NCT01582204
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2012-04
- **Primary completion:** 2026-04
- **Final completion:** 2026-04
- **Target enrollment:** 17 (ACTUAL)
- **Last updated:** 2025-08-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01582204

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01582204, "Evaluate The Utility Of 124I-cG250 for The Early Detection Of Response to Therapy In Patients With Metastatic Renal Cell Carcinoma". Retrieved via AI Analytics 2026-07-02 from https://api.ai-analytics.org/clinical/NCT01582204. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*